The nuclear receptor superfamily regulates diverse signals that are central to the formation and homeostasis of the mammary gland. The postgenomic description of the superfamily conjoined with profiling approaches (1) reveals that breast myoepithelial and epithelial cells express a rich cohort of nuclear receptors, many of which display overt nutrient-sensing capacity for micronutrients and macronutrients alongside the estrogen receptors (ERα and ERβ; refs. 2–6). Several of the diet-sensing nuclear receptors, such as the VDR, preferentially form heterodimers with retinoid X receptors whereas the ERs preferentially heterodimerize with one another. For the nuclear receptors to regulate transcriptional responses, many of which display overt nutrient-sensing capacity for micronutrients and macronutrients alongside the estrogen receptors (ERα and ERβ; refs. 2–6). Several of the diet-sensing nuclear receptors, such as the VDR, preferentially form heterodimers with retinoid X receptors whereas the ERs preferentially heterodimerize with one another. For the nuclear receptors to regulate transcriptional programs, these dimers must be contained as subunits in either large gene coactivator or corepressor complexes. In the absence of ligand, receptors exist in an apo state as part of large complexes (~2.0 MDa; ref. 7), associated with corepressors (e.g., NCoR1, NCoR2/SMRT, and TRIP15/Alien), and bound to response element sequences. These complexes actively recruit a range of enzymes that posttranslationally modify histone tails (e.g., histone deacetylases and methyltransferases) and thereby facilitate gene transcription (9–11). Thus, cofactor expression is critical to determine cellular sensitivity to ligand although the specificity of receptor and either coactivator or corepressor interactions remains to be established fully.

In vivo studies on vdr knockout mice show the requirement for 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3] for mammary gland function and differentiation (12). Parallel studies by ourselves and others have found epidemiologic links between the incidence of breast cancers and low serum 25(OH)D3 levels (13, 14); the risk is compounded by specific VDR polymorphisms (15, 16). In vitro studies show that MDA-MB-231 and other cancer cells show a spectrum of insensitivity toward 1α,25(OH)2D3 (17, 18). Taken together, these data suggest that functional VDR-mediated signaling is required for correct gland function and that 1α,25(OH)2D3-deficient environments

Altered Nuclear Receptor Corepressor Expression Attenuates Vitamin D Receptor Signaling in Breast Cancer Cells

Claire M. Banwell,1 Donia P. MacCartney,1 Michelle Guy,4 Alice E. Miles,1 Milan R. Uskokovic,3 Janine Mansi,4 Paul M. Stewart,1 Laura P. O’Neill,2 Bryan M. Turner,2 Kay W. Colston,4 and Moray J. Campbell1

Abstract Purpose: We hypothesized that deregulated corepressor actions, with associated histone deacetylation activity, epigenetically suppressed vitamin D receptor (VDR) responsiveness and drives resistance towards 1α,25-dihydroxyvitamin D3.

Experimental Design: Profiling, transcriptional, and proliferation assays were undertaken in 1α,25(OH)2D3-sensitive MCF-12A nonmalignant breast epithelial cells, a panel of breast cancer cell lines, and a cohort of primary breast cancer tumors (n = 21).

Results: Elevated NCoR1 mRNA levels correlated with suppressed regulation of VDR target genes and the ability of cells to undergo arrest in G1 of the cell cycle. A similar increased ratio of corepressor mRNA to VDR occurred in matched primary tumor and normal cells, noticeably in estrogen receptor α-negative (n = 7) tumors. 1α,25(OH)2D3 resistance in cancer cell lines was targeted by cotreatments with either 1α,25(OH)2D3 or a metabolically stable analogue (RO-26-2198) in combination with either trichostatin A (TSA; histone deacetylination inhibitor) or 5-aza-2’-deoxycytidine (DNA methyltransferase inhibitor). Combinations of vitamin D3 compounds with TSA restored VDR antiproliferative signaling (target gene regulation, cell cycle arrest, and antiproliferative effects in liquid culture) to levels which were indistinguishable from MCF-12A cells.

Conclusions: Increased NCoR1 mRNA is a novel molecular lesion in breast cancer cells, which acts to suppress responsiveness of VDR target genes, resulting in 1α,25(OH)2D3 resistance and seems to be particularly associated with estrogen receptor negativity. This lesion provides a novel molecular diagnostic and can be targeted by combinations of vitamin D3 compounds and low doses of TSA.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Moray J. Campbell, Institute of Biomedical Research, Endocrinology and Metabolism, University of Birmingham Medical School, Wolfson Drive, Edgbaston, Birmingham, United Kingdom. Phone: 44-121-415-8713; Fax: 011-44-121-415-8712; E-mail: m.j.campbell@bham.ac.uk.

© 2006 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-05-1218

Human Cancer Biology

Clin Cancer Res 2006;12(7) April 1, 2006 2004 www.aacrjournals.org

Downloaded from clinicanesthesiology.org on April 10, 2017. © 2006 American Association for Cancer Research.
and/or cellular mechanisms which suppress sensitivity to 1α,25(OH)2D3 are both associated with malignancy. The mechanisms for cellular 1α,25(OH)2D3 insensitivity in breast cancer are as yet unclear and limit therapeutic applications, although a lack of a functional VDR alone cannot explain resistance (17, 19).

We have previously proposed and investigated epigenetic mechanisms as the basis for corruption of VDR signaling in prostate cancer (20, 21). In the current study, we have used these findings for the basis of investigation of nuclear receptor corepressor expression and activity to derive breast cancer insensitivity towards 1α,25(OH)2D3. By contrast, other workers have suggested that NCoR1 is down-regulated in ERα-positive breast cancers as a mechanism of escaping endocrine restraint by tamoxifen (22–25). It thus remains to be resolved which are the pivotal interactions of corepressors, either to drive insensitivity to antimitotic receptors such as the VDR or to play a role in evoking tamoxifen resistance. In the current study, we have investigated the potential for corepressor-mediated mechanisms to attenuate VDR signaling pathways in both ERα-positive and ERα-negative cell line and tumor backgrounds.

### Materials and Methods

**Vitamin D3 compounds and epigenetic inhibitors.** 1α,25-dihydroxy-16,23Z-diene-26,27-heaxafluoro-19-nor vitamin D3 (RO-26-2198; refs. 26–31), trichostatin A (TSA), and 5-aza-2′-deoxycytidine (5-aza-dCyd; Sigma, Poole, United Kingdom) were all stored as 1 mmol/L stock solutions in ethanol at −20°C.

**Cell culture.** The breast cancer cell lines T-47D, ZR-75-1, MCF-7, and MDA-MB-231 were supplemented with 100 units/mL penicillin, 100 µg/mL streptomycin, and 10% fetal bovine serum (Life Technologies). T-47D, ZR-75-1, and T47-D. Growth media containing varying concentrations of 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) and vitamin D3 analogue were added to a final volume of 100 µL/well and the plates were incubated for 96 hours, with redosing after 48 hours. After the incubation period, 100 µL of nucleotide releasing reagent were added to each well and left for 15 minutes at room temperature. Liberated ATP was quantitated by adding 20 µL of ATP monitoring reagent (containing luciferin and luciferase) and measuring luminescence with a microplate luminometer (Berthold Detection Systems, Fisher Scientific). ATP levels were recorded in relative luciferase units and inhibition of proliferation was expressed as a percentage of control. All experiments were repeated in triplicate wells in three separate experiments.

**Clonal proliferation in soft agar.** Trypsinized and washed single-cell suspensions of cells from 80% confluent cultures were enumerated and plated into 24-well flat-bottomed plates (Costar, Buckingham, United Kingdom) using a two-layer soft-agar system with a total of 1 × 10³ cells per well in a total volume of 600 µL/well. Both layers were prepared with sterile agar (1%) that had been equilibrated previously at 42°C. TSA and/or 1α,25(OH)2D3 was added to the wells before the addition of the feeder layer (20% FCS, 40% RPMI, 40% agar). The cells were mixed into the top layer [20% FCS, 30% RPMI, 30% agar, 18% medium containing cells, 1% β-glutamine (100 mg/mL), 1% β-mercaptoethanol (1 mmol/L)] and plated onto the preset under layer. After 14 days of incubation at 37°C in a humidified atmosphere of CO₂ in air, the colonies (>50 cells) were counted under an inverted microscope. All experiments were done thrice in triplicate.

**Cell cycle analysis.** The effect on the cell cycle distribution of vitamin D₃ compounds, alone and in combination with TSA, was measured by staining cell DNA with propidium iodide. Briefly, T25 flasks were seeded with 2.5 × 10⁵ subconfluent, exponentially proliferating cells, exposed to either agent at time 0 (and redosed after 48 hours in 72-hour assays). At a total of 24 and 72 hours, cultures were harvested, counted, and 1 × 10⁶ cells were stained with propidium iodide buffer [10 µg/mL propidium iodide, 1% (v/v) Triton X-100, 100 µmol/L sodium chloride (Sigma)]. Cell cycle distribution was determined using a Becton Dickinson Flow Cytometer and CellFIT Cell Cycle Analysis software. Each condition was examined in triplicate experiments.

**Quantitative reverse transcription-PCR.** Cells were seeded at low and high densities (2 × 10⁴/cm² and 8 × 10⁴/cm², respectively). The subconfluent cultures were harvested after 24 hours whereas the high-density cultures were cultured until reaching confluence (~48 hours). For treatment, the cells were seeded as subconfluent conditions and treated with fresh medium or vitamin D₃ compounds alone or in combination with TSA as indicated. Total RNA was extracted using the GenElute RNA extraction system (Sigma) according to the instructions of the manufacturer. The cDNA was prepared from RNA (1 µg) that was initially heated to 70°C for 5 minutes with 100 pmol random hexamers (Promega). The RNA was then added to an 18-µL reaction mix, which contained a final concentration of 10 units of avian myeloblastosis virus, 1× reaction buffer, 1 unit of RNase inhibitor, and 1 mmol/L DNase, 10 µL of 10× RQ1 buffer, and 80 µL of H₂O to each column, followed by 15-minute incubation at room temperature. RNA was eluted in 30 µL of RNase-free water and stored at −70°C.

**Liquid proliferation assay.** The action of individual agents alone and in combination was examined using a bioluminescent technique to measure changes in liberated cellular ATP per treatment well (ViatLight HS, LumITech, Nottingham, United Kingdom), with previously optimized conditions, according to the instructions of the manufacturer. This assay has proved to yield a linear relationship between ATP levels in the plate and a wide range of cell numbers. Therefore, inhibition of proliferation can be readily measured in test wells by measuring the decrease in ATP levels relative to untreated wells (20).

Briefly, cells were plated in 96-well white-walled tissue culture treated plates (Fisher Scientific Ltd., Loughborough, United Kingdom) at either 2 × 10³ per well (MCF-7 and MDA-MB-231) or 4 × 10³ per well (MCF-12A, ZR-75-1, and T47-D). Growth media containing varying concentrations of 5-aza-dCyd, TSA, 1α,25(OH)2D3, and vitamin D3 analogue were added to a final volume of 100 µL/well and the plates were incubated for 96 hours, with redosing after 48 hours. After the incubation period, 100 µL of nucleotide releasing reagent were added to each well and left for 15 minutes at room temperature. Liberated ATP was quantitated by adding 20 µL of ATP monitoring reagent (containing luciferin and luciferase) and measuring luminescence with a microplate luminometer (Berthold Detection Systems, Fisher Scientific). ATP levels were recorded in relative luciferase units and inhibition of proliferation was expressed as a percentage of control. All experiments were repeated in triplicate wells in three separate experiments.
deoxynucleotide triphosphates. Each reaction was heated for 30 minutes at 37°C, followed by 5 minutes at 95°C.

Expression of specific mRNAs was quantitated using the ABI PRISM 7700 Sequence Detection System. Each sample was amplified in triplicate wells in 25-μl volumes containing 1× TaqMan Universal PCR Master Mix [3 mmol/L Mn(OAc)₂, 200 μmol/L deoxynucleotide triphosphates, 1.25 units AmpliTaq Gold polymerase, 1.25 units AmpErase UNG], 3.125 pmol FAM-labeled TaqMan probe, and 22.5 pmol primers. All reactions were multiplexed with preoptimized control primers to ensure parallel amplification with VIC-labeled probe for 18S rRNA (Perkin-Elmer Biosystems, Warrington, United Kingdom). Primer and probe sequences were previously described (20) and were designed for the current study [VDUP-1 forward primer, GCCTGCTGTTGCTCTCAG; VDUP-1 reverse primer, TGGTCTCCTCGAGTGGATTGTCATGGAA; VDUP-1 reverse primer, TGGTCTCCTCGA-GTTGCCTGGAT; VDUP-1 probe, TTTGACGGTGGAGAACTCTTTAGCCGT] or were provided from Assay-on-Demand (cytokeratin 19, Perkin-Elmer Biosystems). Reactions were cycled as follows: 50°C for 2 minutes, 95°C for 10 minutes; then 44 cycles of 95°C for 15 seconds and 60°C for 1 minute. Data were expressed as Ct values (the cycle number at which logarithmic PCR plots cross a calculated threshold line) and used to determine ΔCt values (ΔCt = Ct of the target gene – Ct of the 18S). The data were transformed through the equation $2^{-\Delta\Delta C}$ to give fold changes in gene expression.

To exclude potential bias due to averaging of data, all statistics were done with ΔCt values. Measurements were carried out at least thrice in triplicate wells for each condition.

Western immunoblot analysis. Cells were seeded at low and high densities (2 × 10⁴/cm² and 8 × 10⁴/cm², respectively) and either harvested after 24 hours (subconfluent) or cultured until the high-density cultures reached confluency (72 hours) to give subconfluent and confluent cultures, respectively. Whole-cell lysates were prepared at indicated time points and Western immunoblot analysis was done as previously described (17). Briefly, 30 μg of total protein for each sample were electrophoresed on an SDS-polyacrylamide gel, transferred onto polyvinylidene difluoride membrane (Immobilon-P, Millipore, Bedford, MA), and blocked with TBS-Tween 20 containing 5% milk powder for 1 hour. For detection of cyclin E, a rabbit polyclonal antibody (C4976, Sigma) was diluted 1:500. The secondary antibody was horseradish peroxidase conjugated (Amersham, Buckinghamshire, United Kingdom) and diluted 1:2,000. Proteins were detected using enhanced chemiluminescence (Amersham, United Kingdom) and diluted 1:2,000. Proteins were detected using enhanced chemiluminescence (Amersham) and autoradiography. To ensure even loading and transfer of protein, membranes were stripped, washed for 15 minutes with TBS-Tween 20, and incubated at 1:5,000 dilution with primary mouse monoclonal β-actin antibody (AC-15, Sigma). An antimonospecific-membrane horseradish peroxidase secondary antibody was used at 1:3,000 and signals were developed with enhanced chemiluminescence and autoradiography as described above. To quantify the relative changes in protein levels, densitometric analysis was done on the autoradiographs and values were normalized to β-actin levels.

### Statistical analysis

The interactions of two compounds were assessed by measuring the mean effect of either compound acting alone ($±$ SE; refs. 20, 21, 33). The combination of the mean effect for each compound acting alone was the predicted combined inhibition. The mean observed combined inhibition was then compared with this value using the Student’s $t$ test. Classification of the inhibitory effects were as follows: strong additive effects were those with an experimental value significantly greater than the predicted value; additive effects were those in which the experimental value did not significantly differ from the predicted value; and subadditive effects were those in which the experimental value was significantly less than the predicted value.

### Results

**Breast cancer cells show suppressed antiproliferative and gene-regulatory responses towards $1\alpha,25(OH)_2D_3$.** To confirm the extent of the suppressed responsiveness towards $1\alpha,25(OH)_2D_3$, we compared the effect of $1\alpha,25(OH)_2D_3$ on the proliferation of a panel of breast cancer cell lines with that on nonmalignant MCF-12A cells using clonal proliferation in soft agar and liquid proliferation assays. MCF-12A cells were significantly and acutely inhibited with ED₅₀ of ~20 and ~300 nmol/L in the soft-agar and liquid media, respectively (Table 1). Complete inhibition of clonal proliferation in soft agar was achieved at 100 nmol/L (ED₉₀ = 70 nmol/L), but not in liquid proliferation assays. In contrast, the malignant cell lines displayed a spectrum of reduced sensitivities towards $1\alpha,25(OH)_2D_3$ (Table 1). T47-D was the most sensitive cell line, with an ED₅₀ in colony formation assay comparable to that of MCF-12A, although it did not display an ED₉₀ value. The remaining lines all showed greater ED₅₀ values in soft agar than MCF-12A cells (Table 1). Indeed, MDA-MB-231 cells did not achieve an ED₅₀ even at 1,000 nmol/L. The responses of the cancer cell lines towards $1\alpha,25(OH)_2D_3$ in the liquid proliferation assay were all suppressed, compared with MCF-12A cells, with ED₅₀ values not being achieved.

In contrast to the differential sensitivity displayed by MCF-12A and the breast cancer cell lines towards $1\alpha,25(OH)_2D_3$, all cell lines displayed comparable and significant responses towards the histone deacetylating inhibitor TSA. The responses to the methytransferase inhibitor 5-aza-dCyd were more heterogeneous (Table 1).

In an attempt to characterize more fully the apparent insensitivity towards $1\alpha,25(OH)_2D_3$, we investigated the basal

### Table 1. Cell sensitivities towards $1\alpha,25(OH)_2D_3$, TSA, and 5-aza-dCyd

<table>
<thead>
<tr>
<th>Cell line</th>
<th>ED₅₀CP 1α,25(OH)₂D₃ (nmol/L)</th>
<th>ED₅₀LP 1α,25(OH)₂D₃ (nmol/L)</th>
<th>ED₂₅ LP TSA (nmol/L)</th>
<th>ED₅₀LP TSA (nmol/L)</th>
<th>ED₂₅LP 5-aza-dCyd (nmol/L)</th>
<th>ED₅₀LP 5-aza-dCyd (nmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCF-12A</td>
<td>20</td>
<td>300</td>
<td>25</td>
<td>40</td>
<td>85</td>
<td>130</td>
</tr>
<tr>
<td>T47-D</td>
<td>15</td>
<td>≥1,000</td>
<td>10</td>
<td>45</td>
<td>110</td>
<td>≥8,000</td>
</tr>
<tr>
<td>ZR-75-1</td>
<td>100</td>
<td>≥1,000</td>
<td>35</td>
<td>100</td>
<td>740</td>
<td>≥8,000</td>
</tr>
<tr>
<td>MCF-7</td>
<td>100</td>
<td>≥1,000</td>
<td>25</td>
<td>45</td>
<td>65</td>
<td>1,825</td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>≥1,000</td>
<td>≥1,000</td>
<td>15</td>
<td>30</td>
<td>85</td>
<td>8,000</td>
</tr>
</tbody>
</table>

NOTE: Cellular responses were screened on two different assay formats, clonal proliferation (CP) in soft agar in 24-well plates and liquid proliferation (LP) in 96-well plates. The ED₅₀ and ED₉₀ were interpolated from dose-response graphs.
and regulated levels of the established VDR target genes CYP24, GADD45α, and VDUP-1 in MCF-12A and MDA-MB-231 cells. During exponential proliferation, the basal levels of CYP24 and VDUP-1 were significantly elevated (78- and 4.3-fold, respectively; \( P < 0.0001 \)) in MDA-MB-231 compared with MCF-12A cells whereas GADD45α did not significantly differ between cell types (data not shown).

The 1α,25(OH)\(_2\)D\(_3\)-mediated accumulation of target gene mRNA reflected the suppressed antiproliferative responses. Thus, in MCF-12A cells, there was a clear 60-fold increase in CYP24 occurring after 1-hour incubation with 100 nmol/L 1α,25(OH)\(_2\)D\(_3\). Expression essentially plateaued after 3 hours at 10,000- to 100,000-fold increases, compared with control, and was sustained for the duration of the analysis (16 hours). The dynamics in MDA-MB-231 cells was similar but the amplitude was considerably lower (23-fold induction after 6-hour treatment with 1α,25(OH)\(_2\)D\(_3\); \( P < 0.0001 \)) and thereafter reached a plateau of ~100-fold (Fig. 1A).

A similar, but not so striking, suppressed VDR responsiveness was seen with the other two gene targets, which are more directly associated with antiproliferative VDReffects (20, 34–38). GADD45α mRNA expression patterns in MCF-12A cells showed significant peaks at 4 hours (1.4-fold; \( P < 0.05 \)), which was sustained up to 8 hours; after which, a subsequent 2.1-fold increase occurred at 12 hours (\( P < 0.05 \)) and decreased thereafter. In MDA-MB-231 cells, the pattern was similar but the magnitude was suppressed at all time points, notably at the 12-hour time point (Fig. 1B). VDUP-1 mRNA displayed a clear early peak increase after 1 hour (1.7-fold; \( P < 0.05 \)) in MCF-12A cells but was absent in MDA-MB-231 cells, although a more modest significant peak was detected at 6 hours (Fig. 1C). In both cell lines, there were cyclical, modest, but not significant, modulation of the VDR at 1, 4, and 7 hours (data not shown). Together, these data suggest that both the antiproliferative and gene regulatory effects of 1α,25(OH)\(_2\)D\(_3\) were repressed in breast cancer cell lines compared with nontumorigenic MCF-12A cells.

Expression and regulation of VDR and corepressors correlate with reduced 1α,25(OH)\(_2\)D\(_3\) sensitivity. We hypothesized that in the cancer cell line panel, the suppressed cellular responses towards 1α,25(OH)\(_2\)D\(_3\) (Table 1) and VDR target gene expression (Fig. 1) were determined by an altered relative ratio of the VDR and either one or all of the VDR interactive corepressors. We therefore compared the basal expression of VDR, NCoR1, NCoR2/SMRT, and TRIP15/Alien in malignant T47-D, ZR-75-1, MCF-7, and MDA-MB-231 to that in MCF-12A cells (Fig. 2A). T47-D cells displayed similar expression levels of VDR and the three corepressors compared with MCF-12A, which reflected a comparable sensitivity towards 1α,25(OH)\(_2\)D\(_3\). In contrast, the three remaining cell lines all displayed significant reductions in VDR, coupled with variable changes in corepressor expression. MCF-7 and MDA-MB-231 cells had significantly elevated NCoR1 expression (2- and 1.7-fold increase, respectively; \( P < 0.05 \)). Interestingly, TRIP15/Alien was also significantly elevated in MCF-7 cells (1.8-fold; \( P < 0.05 \)) but modestly reduced in MDA-MB-231 cells. Consequently, in the 1α,25(OH)\(_2\)D\(_3\)-resistant cancer cell lines, the ratio of NCoR1 to VDR is increased compared with the normalized one in MCF-12A cells, which is arbitrarily set at 1:1. Thus, in exponentially proliferating MDA-MB-231 cells, the ratio of NCoR1 to VDR is 14:1 (Table 2).
We sought to dissect further the dynamic expression patterns of the corepressors relative to the VDR and, therefore, we investigated the expression profiles in the four cancer cell lines under differing proliferation conditions. Cell cycle analyses confirmed that subconfluent MCF-7 cultures had 43 ± 2.3% of cells in G1 and, on confluence, this was significantly increased to 62 ± 3.4% (P < 0.05). Subconfluent MDA-MB-231 cultures had 38 ± 1.7% of cells in G1 and, on confluence, this was significantly increased to 60 ± 4.2% (P < 0.05). Similar patterns were seen in T47-D and ZR-75-1 (data not shown). These effects were confirmed with elevated cyclin E levels in subconfluent versus confluent cultures (Fig. 2B).

T47-D cells displayed a clear, significant reduction in the levels of NCoR1 and TRIP15/Alien mRNA at confluence (0.6- and 0.5-fold reduction, respectively, relative to same cell exponential controls; P < 0.05; Fig. 2C). MDA-MB-231 cells, which had significantly higher basal levels of NCoR1 compared with exponentially proliferating T47-D cells, displayed no down-regulation of NCoR2/SMRT, NCoR1, or TRIP15/Alien mRNA in confluent compared with subconfluent cultures. However, comparable analyses in MCF-7 cells revealed a significant reduction in NCoR1 (0.7-fold; P < 0.05) on confluence (Fig. 2C). Viewed in this way, the graded ability to regulate corepressors, and in particular NCoR1, also correlates closely with 1α,25(OH)2D3 sensitivity (Table 2; Fig. 2C). Together these data support a model where NCoR1 is up-regulated in cells and this level is sustained, irrespective of proliferation status, in the most 1α,25(OH)2D3 recalcitrant cells.

Corepressors are elevated in ERα-negative tumors. To investigate further the significance of deregulated corepressor expression in breast cancer, we examined 21 matched tumor and normal breast cancer samples. To allow for epithelial enrichment in the tumor samples, the relative levels of corepressors were normalized to cytokeratin 19 mRNA, an established marker of mammary epithelial cells (39). There was considerable variation in the level of the VDR in both the ERα-positive (14 of 21) and ERα-negative (7 of 21) tumors with a mean fold change of 4.9 ± 2.1 and 11.8 ± 7.3, respectively, compared with the matched normal, although there was significant variation (Fig. 3A).

These data were then transformed further by normalizing the corepressor expression data to the level of VDR in tumor sample to reveal the ratios of corepressor to VDR, which are shown in Fig. 3B to D. This ratio was noticeably increased in the ERα-negative tumors whereas it was decreased in the ERα-positive tumors. Thus, the mean ratio of the NCoR1 to VDR was 0.25 ± 0.1:1 in the ERα-positive tumors and 4.2 ± 1.4:1 in the ERα-negative tumors, with similar changes in the ratios of SMRT/NCoR2 and TRIP15/Alien to VDR. Interestingly, the level of either NCoR1 or SMRT/NCoR2 positively correlated with the VDR [R2 = 0.45 and 0.66; P < 0.0006 and P < 4 × 10−6, respectively], suggesting that the levels of corepressors were coregulated with the VDR.

Targeting elevated corepressor levels in 1α,25(OH)2D3-insensitive cancer cell lines with histone deacetylation or methylation inhibitors. The above data indicate that corepressors are elevated in breast cancer cell lines and in primary cancer tissue, notably in ERα-negative tissue. Furthermore, at least in cell lines, deregulation of NCoR1 expression correlates with diminished responsiveness to 1α,25(OH)2D3. These data suggest that elevated levels of corepressors may inappropriately sustain acetylation of histone lysine residues and thereby

Fig. 2. Fold elevation of nuclear corepressor mRNA levels in breast cancer cell lines. A, VDR and corepressor mRNA levels measured by quantitative reverse transcription-PCR in T47-D, ZR-75-1, MCF-7, and MDA-MB-231 compared with MCF-12A nonmalignant breast epithelial cells. Total mRNA was isolated from triplicate cultures in mid-exponential phase, reverse transcribed, and the target genes amplified in triplicate as described in Materials and Methods. *, P < 0.05; **, P < 0.01; ***, P < 0.001. B, protein was isolated from parallel subconfluent (S) and confluent (C) MCF-7 and MDA-MB-231 cells (Materials and Methods) and resolved by SDS-PAGE and probed with antibody to cyclin E. Representative blots are shown with the position of the proteins indicated on the left. Blots were subsequently stripped and reprobed for β-actin. C, the fold reduction in the mRNA levels of NCoR1, NCoR2/SMRT, and TRIP15/Alien was measured in confluent cultures of T47-D, ZR-75-1, MCF-7, and MDA-MB-231, compared with subconfluent controls, by quantitative reverse transcription-PCR. Points, mean of three separate experiments amplified in triplicate wells; bars, SE.
reduce the ability of the VDR to initiate transcription. Histone deacetylation leading to chromatin condensation has been shown to form a template for DNA methyltransferases to initiate a more stable long-term silencing of gene loci (40–42). Therefore, we reasoned that the relative 1α,25(OH)2D3 insensitivity associated with elevated NCoR1 could be countered by cotreatment with minimally active ED25 doses of the histone deacetylase inhibitor (TSA) and the DNA methyltransferase inhibitors (5-aza-dCyd), either alone or in combination with vitamin D3 compounds.

Furthermore, a limitation of 1α,25(OH)2D3 function is its rapid metabolism by the catabolic enzyme 24-hydroxylase, encoded by the VDR target gene CYP24, and therefore we and others have synthesized a range of vitamin D3 analogues which are protected from 24-hydroxylase–mediated metabolism. Thus, RO-26-2198 (27, 28) was used to control for the 24-hydroxylase metabolism of ligand. Then, we undertook a comprehensive profile of combinatorial effects against MCF-12A and a panel of breast cancer cell lines using combinations of vitamin D3 compounds [1α,25(OH)2D3 or RO-26-2198 (100 nmol/L)] with TSA and 5-aza-dCyd, either alone or together.

These studies revealed that generally the strongest individual agent effects were observed in MCF-12A cells. That is, whereas MCF-12A cells were potently inhibited by each agent individually, they did not display any significant co-operativity. Indeed, with a few cotreatments (e.g., with vitamin D3 compounds plus 5-aza-dCyd), the observed effects were actually significantly suppressed compared with the predicted effects. By contrast, there was enhancement of observed over predicted effect by cotreatment with TSA in the cancer cell line models. Importantly, the extent of the co-operative interactions correlated with the altered ratio of NCoR1 to VDR and was most pronounced in the ERα-negative cell line MDA-MB-231. Thus, combinations of RO-26-2198 with TSA were additive in T47-D, whereas in ZR-75-1 and MDA-MB-231, these effects were converted to strong additive interactions (Table 2).

### Table 2. Combinations of vitamin D3 compounds plus either TSA or Aza enhance antiproliferative responses in breast cancer cells

<table>
<thead>
<tr>
<th>Breast epithelial cell line</th>
<th>Ratio of NCoR1 to VDR</th>
<th>1α,25(OH)2D3</th>
<th>5-Aza-dCyd</th>
<th>TSA + 5-aza-dCyd</th>
<th>RO-26-2198</th>
<th>TSA + 5-aza-dCyd</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCF-12A</td>
<td>1:1</td>
<td>P: 63 ± 8</td>
<td>P: 65 ± 7</td>
<td>P: 75 ± 6</td>
<td>P: 48 ± 4</td>
<td>P: 52 ± 4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>O: 56 ± 5</td>
<td>O: 38 ± 5</td>
<td>O: 67 ± 2</td>
<td>O: 52 ± 5</td>
<td>O: 35 ± 5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P &lt; 0.05</td>
<td>P &lt; 0.05</td>
<td>P &lt; 0.05</td>
</tr>
<tr>
<td></td>
<td></td>
<td>O: 47 ± 5</td>
<td>O: 33 ± 6</td>
<td>O: 56 ± 6</td>
<td>O: 52 ± 6</td>
<td>O: 39 ± 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P &lt; 0.05</td>
<td>&lt;0.05</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>ZR-75-1</td>
<td>9:1</td>
<td>P: 18 ± 7</td>
<td>P: 12 ± 7</td>
<td>P: 21 ± 4</td>
<td>P: 16 ± 6</td>
<td>P: 5 ± 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P &lt; 0.005</td>
<td>&lt;0.005</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>O: 30 ± 5</td>
<td>O: 34 ± 6</td>
<td>O: 51 ± 3</td>
<td>O: 29 ± 2</td>
<td>P: 42 ± 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P &lt; 0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.002</td>
</tr>
<tr>
<td>MDA-MB-231</td>
<td>14:1</td>
<td>P: 26 ± 2</td>
<td>P: 14 ± 2</td>
<td>P: 48 ± 3</td>
<td>P: 41 ± 4</td>
<td>P: 29 ± 4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>O: 35 ± 8</td>
<td>O: 9 ± 3</td>
<td>O: 41 ± 5</td>
<td>O: 61 ± 2</td>
<td>P: 36 ± 6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>P &lt; 0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**NOTE:** 1α,25(OH)2D3 or RO-26-2198 (100 nmol/L) was combined with TSA (25 nmol/L for MCF-12A and 15 nmol/L for cancer cell lines) or 5-aza-dCyd (250 nmol/L). Proliferation inhibition was measured in liquid media after 96 hours, with redosing after 48 hours. The predicted (P) values represent the inhibition of vitamin D3 compounds plus TSA cotreatment. Thus, mid-exponentially proliferating cells were either of these responses. After 24-hourexposure to 1α,25(OH)2D3 (100 nmol/L), there was a significant accumulation of cells in G1 (62% ± 4%; P < 0.05) compared with 43% in G0-G1 in matched mid-exponentially proliferating control cells and a concomitant reduction in the proportion of cells in S and G2-M phase. In parallel, we measured changes in mitochondrial membrane integrity using JC-1 dye, which dimerizes and fluoresces red in healthy mitochondria compared with monomeric green when membrane potential is lost. This approach measures the early commitment of cells toward apoptosis and therefore was examined at 24 and 48 hours using previously optimized protocols (21). These analyses found only minor, nonsignificant changes, which suggested that the cells were not undergoing apoptosis (data not shown).

Subsequently, we measured the extent to which cotreatments of vitamin D3 compounds plus TSA altered the cell cycle profile in MCF-12A, MCF-7, or MDA-MB-231 cells. The cotreatment with TSA in MCF-12A cells did not enhance the clear effect of 1α,25(OH)2D3 alone. By contrast, the cancer cell lines showed the clearest changes in cell cycle distribution with vitamin D3 compounds and TSA cotreatment. Thus, mid-exponentially proliferating control MCF-7 cells displayed 42% (+1.1%) in G1 and 21% (+1.2%) in G2-M phase. A single treatment with
either 1α,25(OH)2D3 or RO-26-2198 had no significant effect by 24 hours whereas only the combination of RO-26-2198 plus TSA resulted in a significant reduction of cells in G2-M phase to 16% (±0.5%; P < 0.01). A similar pattern was observed in MDA-MB-231 cells where the cotreatments resulted in the clearest accumulation in G1 and loss of cells in G2-M phase. Thus, mid-exponentially proliferating control cells displayed 38% (±3.0%) in G1 and 25% (±2%) in G2-M phase. RO-26-2198 plus TSA resulted in 44% (±2%) of cells in G1 and 17% (±1%) in G2-M phase (P < 0.05). G1 accumulation with RO-26-2198 plus TSA was greater still after 72 hours (50% (±1.5%)) whereas the control cells displayed an accumulation of 38% (±1.5%). Together these data suggest that the cotreatment with agents facilitates co-operative changes in the distribution of the cell cycle, which, in part, contribute to the potency antiproliferative actions.

**Regulation of VDR target genes in MDA-MB-231 cells cotreated with RO-26-2198 plus TSA.** In line with the hypothesis of epigenetically repressed antiproliferative target genes, we investigated the effects on the regulation of the antiproliferative target genes GADD45α, VDUP-1, and the 1α,25(OH)2D3-regulatory CYP24. Time-course studies (0-16 hours) in MDA-MB-231 cells were undertaken to investigate the effects of RO-26-2198 alone and in combination with TSA. Treatments with RO-26-2198 alone revealed that patterns and fold changes of GADD45α, VDUP-1, and CYP24 did not significantly differ between 1α,25(OH)2D3 and RO-26-2198 (Figs. 1 and 4).

By contrast, cotreatment with RO-26-2198 and TSA co-operatively regulated target genes. The induction of GADD45α in MDA-MB-231 cells by either 1α,25(OH)2D3 or RO-26-2198 was characterized by a broad, but suppressed, accumulation of mRNA after 12 hours, and therefore comparable to the pattern observed in MCF-12A cells (Fig. 1B). Only cotreatment with RO-26-2198 and TSA enhanced the magnitude of the 12-hour peak, resulting in a 2.4-fold increase, which was significantly greater than treatment with either RO-26-2198 or TSA alone (P < 0.05; Fig. 4A).

Interestingly, this level was comparable to the induction in MCF-12A cells treated with 1α,25(OH)2D3 alone (Fig. 1B). VDUP-1 induction also showed significant enhancement of mRNA accumulation when cotreated with RO-26-2198 plus TSA, notably at 12 hours (2.1-fold versus 1.1- and 1.6-fold for cotreatment versus TSA and RO-26-2198, respectively; P < 0.05; Fig. 4B).

In contrast to these effects, RO-26-2198 cotreatment with TSA had a complex range of effects on the induction of CYP24. TSA alone had little effect, but at early time points (<5 hours), it squelched RO-26-2198-mediated induction very significantly. For example, at 3 hours, the induction by RO-26-2198 alone was 14.8-fold and TSA significantly reduced this to 6.4-fold (P < 0.0001; Fig. 4C). At later time points, the patterns were reversed and cells cotreated with TSA plus RO-26-2198 displayed significantly enhanced CYP24 mRNA levels (P < 0.0001) compared with either agent alone (data not shown).

**Discussion**

The current study has shown that the spectrum of reduced 1α,25(OH)2D3-responsiveness between nonmalignant breast epithelial cells and cancer cell lines was not determined solely by a linear relationship between the levels of 1α,25(OH)2D3 and VDR. Rather, elevated levels of corepressors, such as NCoR1, in breast cancer cell lines and primary tumors were common and associated with insensitivity towards 1α,25(OH)2D3. In turn, the NCoR1 complex was targeted by cotreatments of vitamin D3 compounds plus histone deacetylation inhibitors, which was associated with increased gene regulatory actions and antiproliferative responses.

![Fig. 3. Expression and altered ratio of VDR to corepressor mRNA levels in matched primary cultures. A, the relative expression of VDR levels in ERα-positive (n = 14) and ERα (n = 7) tumors compared with matched controls. Levels were normalized to expression of the mammary epithelial markers cytokeratin 19. B to D, the ratio of corepressor mRNA to VDR, after normalization to cytokeratin 19, in matched tumor and normal pair as measured by quantitative reverse transcription-PCR as described in Materials and Methods.](www.aacrjournals.org)
VDR target gene regulation studies revealed that each gene target seemed to have a distinct profile of mRNA accumulation, which often differed between the malignant and nonmalignant background. The complex choreography of nuclear receptor-mediated transactivation has only recently emerged and involves cyclical rounds of receptor-coactivator complex assembly, recruitment of members of the large “bridging” DRIP/TRAP/ARC complex, which links the receptor complex to the cointegrators CREB-binding protein/p300, and basal transcriptional machinery (9, 10). In ligand-replete systems, these cycles can be transient (<30 minutes) and include the sequential assembly of receptor complexes followed by subsequent complex disassembly, proteosome-mediated receptor degradation, and/or recruitment of corepressors to remaining receptors to reconstitute repressive complexes (45, 46). More recently, it has emerged that different response elements respond to ligand in a relatively asynchronous manner with separate, temporal patterns of receptor associations with coactivators and corepressors (e.g., vitamin D response element on the promoter/enhancer region of the CYP24 gene; ref. 47).

The pulsatile mRNA accumulation patterns of the target genes VDUP-1 and GADD45α may reflect such spatiotemporal cycling recruitment of apo and holo receptor megacomplexes at individual vitamin D response element on the promoter/enhance of target genes. We propose that deregulated corepressor levels shift the dynamic equilibrium between apo and holo receptor conformations to histone deacetylation around the vitamin D response element and favor transcriptional repression. Thus, VDR gene targets (e.g., CYP24, GADD45α, and VDUP-1) are less responsive to 1α,25(OH)2D3 in MDA-MB-231 cells compared with MCF-12A cells. Somewhat paradoxically, the basal levels of CYP24 and VDUP-1 are elevated in MDA-MB-231 compared with MCF-12A cells, which suggests that the responsiveness, rather than the absolute expression levels, is targeted for disruption; certainly, there is a clear advantage to be gained in cancer cells by having elevated basal levels of CYP24, which is also a target for amplification in breast cancer (48).

Increased ratios of corepressor to VDR correlated with loss of sensitivity towards 1α,25(OH)2D3 and elevated proliferative status, suggesting that VDR responsiveness is repressed in post-G1 cells. Corepressor down-regulation in G1 may afford a “window” of sensitivity towards antimitotic hormones such as 1α,25(OH)2D3. Possibly reflective of their deregulated proliferative status, frequent corepressor up-regulation was found in ERα-negative primary tumors. Interestingly, in the primary...
tumor material, NCoR1 and SMRT/NCoR2 levels were positively correlated with VDR levels. These data suggest that where the VDR is elevated, it may actually provide a benefit to the tumor. First, the increased ratio of NCoR1 to VDR may drive apo receptor complexes to assemble on the promoter/enhancer region of target genes and, therefore, form a template for subsequent more stable epigenetic silencing of these regions. Second, it may allow cytoplasmic VDR actions to suppress apoptosis via nontranscriptional interactions (49). Elevation of NCoR1 and NCoR2/SMRT found in the current study may in part explain the relative insensitivity of other breast cancer cell lines (BT-474, BT-20, HBL-100, and SK-BR-6) found by others (18, 50). Equally, we surveyed five known ERα-negative cell lines and found >2-fold increase in NCoR1 expression levels in four (MDA-MB-175, BT-20, HBL100, and HMT3532) compared with T47-D cells (data not shown).

Metabolism of 1α,25(OH)2D3 limits VDR-mediated signaling. Consequently, we focused on a metabolically stable analogue of 1α,25(OH)2D3. However, the potency of this analogue was significantly enhanced further by the cotreatment with TSA, suggesting that ligand availability is not the sole rate-limiting factor in gene regulation. These studies revealed that increased ratio of corepressor to VDR predicted enhanced responsiveness to combinations of vitamin D3 compounds plus TSA. These antiproliferative responses were associated with increased G1 accumulation and reflected the acute antiproliferative response displayed by MCF-12A cells towards 1α,25(OH)2D3. These data are supported by our earlier preliminary study, which showed significant strong additive effects in clonogenic assays with MDA-MB-231 cells treated with 1α,25(OH)2D3 at doses as low as 1 nmol/L combined with TSA (51).

Cotreatment with vitamin D3 compounds plus TSA may act to shift the equilibrium point between the apo and holo receptor complexes to favor a more transcriptionally permissive environment and facilitate transactivation, reflecting the greater metabolic stability of RO-26-2198; cotreatment with TSA significantly increased the levels of GADD45α and VDUP-1, notably at later time points. Parallel studies in prostate cancer also identified that GADD45α induction was repressed in androgen receptor–independent cancer models. Equally, the levels of GADD45α reexpression were comparable to those found in MDA-MB-231 cells and were shown to equate to a significant increase in protein levels (20). By contrast, induction of CYP24 was initially suppressed by the cotreatment with vitamin D3 compounds plus TSA. Other mechanisms are likely to play a part. For example, TSA may act to increase the expression of a negative regulator such as YY1, which has been shown to suppress transcription by the VDR on the CYP24 promoter (52). Presumably, the limited effect of this effect is related to the metabolism of TSA (53).

Collectively, our data support the hypothesis that the actions of the VDR are suppressed by an epigenetic mechanism, which attenuates the ability to regulate target genes. In support of this, we found that cancer cells with reduced antiproliferative sensitivity towards 1α,25(OH)2D3 also showed suppressed regulation of three VDR target genes, which in turn correlated with the ratios of corepressor to VDR. In addition, a similar spectrum of ratios was found in ERα-negative primary tumors. Sensitivity of breast cancer cell lines towards 1α,25(OH)2D3 could be enhanced by cotreating with histone deacetylation inhibitors, again most notably in the ERα-negative breast cancer models, underscoring the role of corepressors. This in turn was associated with reexpression of antiproliferative target genes, such as GADD45α, to a level that was comparable to that observed in nonmalignant models. GADD45α is an ideal candidate for a repressed VDR target gene (i.e., basal expression is comparable in all cell models) but regulation is suppressed in 1α,25(OH)2D3-insensitive cells.

From these data, we suggest a model whereby in ERα-positive disease, NCoR1 and NCoR2/SMRT levels are reduced, reflected by the reduced ratio of expression to VDR, thereby enhancing estrogenic signaling. By contrast, ERα-negative tumors, which have arisen either de novo or as a result of tamoxifen treatment, are not reliant on estrogenic hormones, and instead elevation of NCoR1 silences VDR and other antiimitotic nuclear receptors. These findings reflect our previous studies in prostate cancer (20, 21). Equally these patterns will be compounded by the roles that these corepressors play in regulating other transcription factor actions (54–56). The current study adds to a growing body of data, which underscores the importance of the coactivator/corepressor milieu to determine nuclear receptor actions in physiology and pathophysiology (57–61).

Finally, these studies suggest that the VDR is not overtly disrupted by genetic or cytogenetic mechanisms in cancer, but rather epigenetic mechanisms selectively attenuate the transcriptional responsiveness. Such mechanisms most likely disrupt other receptors, resulting in reduced sensitivity to a wide range of dietary-derived macronutrient and micronutrient ligands. Thus, measurement of ratios of corepressor to receptors, such as VDR in tumor samples, may have significant prognostic and therapeutic value. The current study has highlighted the potential to establish novel chemotherapies centered around histone deacetylation inhibitors, such as TSA, or the clinically relevant suberoylanilide hydroxamic acid, in combination with potent dietary-derived nuclear receptor ligands, to deliver a more focused and sustained “anticancer” regimen for estrogen-independent disease.

References

Altered Nuclear Receptor Corepressor Expression Attenuates Vitamin D Receptor Signaling in Breast Cancer Cells

Claire M. Banwell, Donia P. MacCartney, Michelle Guy, et al.


Updated version Access the most recent version of this article at: [http://clincancerres.aacrjournals.org/content/12/7/2004](http://clincancerres.aacrjournals.org/content/12/7/2004)

Cited articles This article cites 59 articles, 21 of which you can access for free at: [http://clincancerres.aacrjournals.org/content/12/7/2004.full.html#ref-list-1](http://clincancerres.aacrjournals.org/content/12/7/2004.full.html#ref-list-1)

Citing articles This article has been cited by 22 HighWire-hosted articles. Access the articles at: [http://clincancerres.aacrjournals.org/content/12/7/2004.full.html#related-urls](http://clincancerres.aacrjournals.org/content/12/7/2004.full.html#related-urls)

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.